{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:12:19Z","timestamp":1760188339358},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1983,9,1]],"date-time":"1983-09-01T00:00:00Z","timestamp":431222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[1983,9]]},"DOI":"10.1016\/0002-9149(83)90625-2","type":"journal-article","created":{"date-parts":[[2004,4,19]],"date-time":"2004-04-19T10:29:35Z","timestamp":1082370575000},"page":"C3-C7","source":"Crossref","is-referenced-by-count":15,"title":["Importance of metabolites in antiarrhythmic therapy"],"prefix":"10.1016","volume":"52","author":[{"given":"Raymond L.","family":"Woosley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan M.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/0002-9149(83)90625-2_BIB1","series-title":"Biological Effects of Drugs in Relation to Their Plasma Concentrations","first-page":"97","article-title":"Are we measuring the right things? The role of active metabolites","author":"Oates","year":"1972"},{"key":"10.1016\/0002-9149(83)90625-2_BIB2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJM197805252982101","article-title":"Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome","volume":"298","author":"Woosley","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/0002-9149(83)90625-2_BIB3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt197722163","article-title":"Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function","volume":"22","author":"Drayer","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0041-008X(79)90486-1","article-title":"Evidence for the biotransformation of procainamide to a reactive metabolite","volume":"50","author":"Freeman","year":"1979","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/0002-9149(83)90625-2_BIB5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0002-9149(80)90016-8","article-title":"Antiarrhythmic efficacy, pharmacokinetics and safety of Nacetylprocainamide in human subjects: comparison with procainamide","volume":"46","author":"Roden","year":"1980","journal-title":"Am J Cardiol"},{"key":"10.1016\/0002-9149(83)90625-2_BIB6","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/0002-9149(81)90225-3","article-title":"Electrophysiologic effects of N-acetylprocainamide in human beings","volume":"47","author":"Jaillon","year":"1981","journal-title":"Am J Cardiol"},{"key":"10.1016\/0002-9149(83)90625-2_BIB7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.7326\/0003-4819-90-5-799","article-title":"Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy","volume":"90","author":"Stec","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/0002-9149(83)90625-2_BIB8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/0003-4819-95-1-18","article-title":"Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome","volume":"95","author":"Kluger","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.1016\/0002-9149(83)90625-2_BIB9","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197912203012506","article-title":"Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide","volume":"301","author":"Lahita","year":"1979","journal-title":"N EngT J Med"},{"key":"10.1016\/0002-9149(83)90625-2_BIB10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM198004173021601","article-title":"Total suppression of ventricular arrhythmias by encainide","volume":"302","author":"Roden","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/0002-9149(83)90625-2_BIB11","first-page":"501A","article-title":"Co-inheritance of deficient oxidative metabolism of encainide and debrisoquine","volume":"29","author":"Woosley","year":"1981","journal-title":"Clin Res"},{"key":"10.1016\/0002-9149(83)90625-2_BIB12","doi-asserted-by":"crossref","unstructured":"Carey EL Jr, Duff HJ, Roden DM, Primm RK, Wilkinson GR, Wang T, Oates JA, Woosley RL. Encainide and its metabolites: comparative effects in man in ventricular arrhythmia and electrocardiographic intervals. J Clin Invest, in press.","DOI":"10.1172\/JCI111241"},{"key":"10.1016\/0002-9149(83)90625-2_BIB13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF00605629","article-title":"Clinical experience of encainide (MJ 9067): a new anti-arrhythmic drug","volume":"16","author":"Kesteloot","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/0002-9149(83)90625-2_BIB14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/01.CIR.64.2.290","article-title":"Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias","author":"Winkle","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/0002-9149(83)90625-2_BIB15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0002-9149(81)90584-1","article-title":"Antiarrhythmic efficacy of encainide and quinidine: validation of a model for drug assessment","volume":"48","author":"Saml","year":"1981","journal-title":"Am J Cardiol"},{"key":"10.1016\/0002-9149(83)90625-2_BIB16","first-page":"440","article-title":"Effects of encainide and metabolites (MJ 14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers","volume":"220","author":"Elharrar","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB17","first-page":"552","article-title":"Antiarrhythmic activity of the O-demethyl metabolite of encainide","volume":"221","author":"Roden","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB18","first-page":"209","article-title":"Comparative antiarrhythmic and local anesthetic actions of encainide and its two major metabolites","volume":"23","author":"Gomoll","year":"1981","journal-title":"Pharmacologist"},{"key":"10.1016\/0002-9149(83)90625-2_BIB19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0002-8703(81)90036-3","article-title":"Malignant ventricular tachyarrhythmias associated with the use of encainide","volume":"102","author":"Winkle","year":"1981","journal-title":"Am Heart J"},{"key":"10.1016\/0002-9149(83)90625-2_BIB20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.1981.tb01123.x","article-title":"The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships","volume":"11","author":"Holford","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/0002-9149(83)90625-2_BIB21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/01.CIR.1.4.576","article-title":"Blood quinidine concentrations as a guide in the treatment of cardiac arrhythmias","volume":"1","author":"Sokolow","year":"1950","journal-title":"Circulation"},{"key":"10.1016\/0002-9149(83)90625-2_BIB22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01060020","article-title":"Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods","volume":"7","author":"Guentert","year":"1979","journal-title":"J Pharmacokin et Biopharm"},{"key":"10.1016\/0002-9149(83)90625-2_BIB23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3109\/00365516309079786","article-title":"Quantitative determination of quinidine in plasma","volume":"15","author":"Cramer","year":"1963","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/0002-9149(83)90625-2_BIB24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinchem\/27.2.308","article-title":"Liquid chromatography and fluorescence spectroscopy compared with a homogeneous enzyme immunoassay technique for determining quinidine in serum","volume":"27","author":"Drayer","year":"1981","journal-title":"Clin Chem"},{"key":"10.1016\/0002-9149(83)90625-2_BIB25","first-page":"816","article-title":"Specific determination of quinidine and (3S)-3-hydroxyquinidine in human serum by high-pressure liquid chromatography","volume":"90","author":"Drayer","year":"1977","journal-title":"J Lab Clin Med"},{"key":"10.1016\/0002-9149(83)90625-2_BIB26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0378-4347(00)82063-0","article-title":"Determination of quinidine and its major metabolites by high-performance liquid chromatography","volume":"162","author":"Guentert","year":"1979","journal-title":"J Chromatogr"},{"key":"10.1016\/0002-9149(83)90625-2_BIB27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0002-9343(64)90018-X","article-title":"Some cellular and metabolic considerations relating to the action of quinidine as prototype antiarrhythmic agent","volume":"37","author":"Conn","year":"1964","journal-title":"Am J Med"},{"key":"10.1016\/0002-9149(83)90625-2_BIB28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cpt197824131","article-title":"Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function","volume":"24","author":"Drayer","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.1980.11","article-title":"Prevalence of high (3S)-3-hydroxyquinidinequinidine ratios in serum, and clearance of quinidine in cardiac patients with age","volume":"27","author":"Drayer","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00003088-197904020-00001","article-title":"Clinical pharmacokinetics of propranolol","volume":"4","author":"Routledge","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/0002-9149(83)90625-2_BIB31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/cpt1979266686","article-title":"Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol","volume":"26","author":"Walle","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB32","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1056\/NEJM198212163072505","article-title":"Oxidation phenotype\u2014a major determinant of metoprolol metabolism and response","volume":"307","author":"Lennard","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/0002-9149(83)90625-2_BIB33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cpt1978246654","article-title":"Lidocaine and its active metabolites","volume":"24","author":"Narang","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/cpt197518159","article-title":"Pharmacokinetics and metabolism of lidocaine in patients with renal failure","volume":"18","author":"Collinsworth","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB35","first-page":"31","article-title":"The convulsant potency of lidocaine and its N-dealkylated metabolites","volume":"186","author":"Blumer","year":"1973","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cpt1979262196","article-title":"Lorcainide II. Plasma concentrationeffect relationship","volume":"26","author":"Meinertz","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/clpt.1983.4","article-title":"Lorcainide disposition kinetics in arrhythmia patients","volume":"33","author":"Kates","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/0002-9149(83)90625-2_BIB38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2165\/00003088-197601060-00003","article-title":"Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure","volume":"1","author":"Drayer","year":"1976","journal-title":"Clin Pharmacokinet"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0002914983906252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0002914983906252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T08:56:24Z","timestamp":1585731384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0002914983906252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,9]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1983,9]]}},"alternative-id":["0002914983906252"],"URL":"https:\/\/doi.org\/10.1016\/0002-9149(83)90625-2","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[1983,9]]}}}